To all: list of competition for StressGen's lead product
HspE7 for cervical dysplasia and cervical cancer.
If you go to this site and do a search for "cervical"
and another search for "warts", you get lists of
clinical trials for cervical dysplasia and cervical cancer.
recap.com
There are 7 companies and 11 trials with 2
products on the market. I've added a bit of value
by including ticker symbols and home pages.
1 of 7.
Developer: Interferon Sciences (IFSC)
interferonsciences.com
Indication: HIV associated cervical dyplasia
Marketer(s): Fujimoto Diagnostics (Japan),
Interferon Sciences
Product: gel formulation of human
leukocyte-derived interferon alfa-n3
Status: Phase 2 in Feb93
Tradename: Alferon N Gel
Disease: Infection - AIDS
Technology: Natural product
Developer: Interferon Sciences
Indication: genital warts (condylomata acuminata)
Marketer(s): Fujimoto Diagnostics
(Japan),Interferon Sciences
Product: human leukocyte-derived interferon
alfa-n3 (injectable)
Status: Market in Feb91
Tradename: Alferon N Injection
Disease: Infection - Antibiotics
Technology: Natural product
The IFSC share price has gone from over $8.00 in
Jan98 to about 50 cents .
2 of 7.
Developer: Ilex Oncology (ILXO)
ilexoncology.com
Indication: cervical intraepithelial dysplasias
Product: polyamine-forming enzyme inhibitor
Status: Phase 2
Tradename: Eflornithine
(DFMO - alpha-difluoromethylornithine)
Disease: Cancer
3 of 7.
Developer: Cantab Pharmaceuticals (CNTBY)
noonanrusso.com
Indication: cervical cancer
Marketer(s): Cantab Pharmaceuticals
Product: recombinant vaccinia virus
for HPV E6 & E7
Status: Phase 2
Tradename: TA-HPV
R&D: Cantab Pharmaceuticals
Client: Cancer Research Campaign
Disease: Cancer, Infection - Antivirals,
Infection - Vaccines
Technology: Recombinant DNA
Developer: Cantab Pharmaceuticals
Indication: HSV-2 (genital warts)
Marketer(s): SmithKline
Product: immunotherapeutic vaccine
Status: Phase II in May96
Tradename: TA-GW
Disease: Infection - Antivirals, Infection -
Vaccines
Technology: Recombinant DNA
4 of 7.
Developer: Biogen (BGEN)
biogen.com
Indication: cervical dysplasia
Marketer(s): Biogen
Product: recombinant human beta interferon 1-a
(glycosylated)
Status: Phase 2
Tradename: Avonex
Disease: Cancer
Technology: Recombinant DNA
I cannot find anything more on Avonex trial
against cervical dysplasia.
Developer: Biogen
Indication: condylomata acuminata (genital warts)
Marketer(s): Schering-Plough
Product: human recombinant interferon alpha 2-b
Status: Market in Jun88
Tradename: Intron-A
Disease: Infection - Antibiotics
Technology: Recombinant DNA
Developer: Biogen
Indication: venereal warts
Marketer(s): Biogen
Product: recombinant human gamma interferon
Status: Phase II
Tradename: Immuneron
Disease: Infection - Antivirals
Technology: Recombinant DNA
5 of 7.
Developer: MedImmune (MEDI)
medimmune.com
Indication: prevention of genital herpes (HPV)
Marketer(s): SmithKline
Product: vaccine of VLPs from
HPV-11 L1 capsid protein
Status: Phase 1 in Feb97
Tradename: MEDI-501
Disease: Infection - Antivirals,
Infection - Vaccines
Technology: Recombinant DNA
MEDIMMUNE FINALIZES VACCINE AGREEMENT
with SmithKline Beecham (SBH)
medimmune.com
A page on the MEDI web site,
medimmune.com
says
"The Company began a Phase 1 clinical trial
with MEDI-501 in February 1997 to evaluate its
safety, tolerance, and immunogenicity.
The trial, which is being conducted at the
University of Rochester Medical Center, is
expected to conclude by year-end. In addition,
the Company has an HPV-18 vaccine candidate
(MEDI-504) and an HPV-16 vaccine candidate
(MEDI-503) in pre-clinical development."
I cannot find anything more on these trials.
6 of 7.
Developer: Cytel (CYTL)
subsidiary "Epimmune"
cytelcorp.com
Indication: late-stage cervical cancer
Marketer(s): Cytel
Product: human papillomarirus (HPV) antigenic
peptide-based therapeutic vaccine
Status: Phase 1-2
Tradename: CY-2121 Theradigm-HPV
Disease: Cancer, Infection - Vaccines
Technology: Recombinant DNA
CYTL share price has gone from $60.00 in mid-96 to about $2.50 today.
7 of 7.
Developer: Gilead (GILD)
gilead.com
Indication: HPV-associated genital warts
Marketer(s): Gilead
Product: nucleotide analog (cidofovir topical gel)
Status: Phase I/II Phase 2 in Mar96.
Tradename: Forvade
Disease: Infection - Antivirals
Technology: Synthetics
Note: GILD's web site tried 84 times to put a
cookie on my PC. A quick look at the web site
shows nothing about this trial.
Heat. |
